Humacyte Reports Accelerating Commercial Adoption, Reports 44% Increase In Hospitals Ordering Symvess To 49 In Q3 2026
– Hospitals that have ordered Symvess® increased 44% during the third quarter, from 34 at the end of the second quarter to 49 as of September 30, 2026.– Commercial momentum continues to build, driven by expanding
More hospitals are ordering Humacyte's product Symvess. When a new medical product spreads to more hospitals, it shows doctors are finding it useful and helpful.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.